Clinical Trial Update: Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating dolutegravir with tenofovir/emtricitabine or lamivudine in HIV-1 infected transgender women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Dolutegravir + Emtricitabine
• Dolutegravir + Tenofovir/lamivudine

Snippet

Sponsor: Fundación Huésped | Conditions: HIV Infections | Phase 4 | Status: COMPLETED